PR.com is a leader in paid and free press release distribution.
To reach journalists, increase online visibility, and attract new customers,
submit via our global online news and press release distribution service to
top search engines, thousands of websites, social media, blogger networks,
as well as via print, broadcast, radio, mobile channels, and more.
ALPCO announces launch of its new highly specific FDA Class I Exempt STELLUX® Chemi Glucagon ELISA. - October 23, 2018 - ALPCO
Epitope Diagnostics, Inc. (EDI), is pleased to announce it has received certification for the Vitamin D Standardization Program (VDSP) for vitamin D measurement in the EDI™ Total 25-OH Vitamin D EIA Kit. CDC’s Vitamin D Standardization-Certification Program (VDSCP) evaluates the accuracy... - October 21, 2018 - Epitope Diagnostics, Inc.
ALPCO announces the first recipient of its new young investigators award, the Diabetes Research Travel Grant. - October 17, 2018 - ALPCO
ALPCO announces that its quality management system recently received the distinguished ISO 13485:2016 certification from Intertek to ensure the quality, safety and efficacy of its products in the clinical diagnostics field. - October 09, 2018 - ALPCO
Epitope Diagnostics, Inc. is pleased to announce it has been selected to take part in MetroConnect 2018, an export assistance program run by the World Trade Center San Diego (WTC) and designed to help San Diego companies accelerate their global growth.
This program will allow Epitope Diagnostics to... - September 23, 2018 - Epitope Diagnostics, Inc.
ALPCO will promote the expansion of its STELLUX® Chemiluminescence ELISA platform, as well as its current therapeutic drug monitoring portfolio, gastroenterology testing panel, and assay qualification program at AACC’s 70th Annual Clinical Lab Expo. - July 25, 2018 - ALPCO
ALPCO and InSphero announce partnership to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. - July 24, 2018 - ALPCO
ALPCO, a leading producer of research and clinical immunoassays, recently announced the launch of its STELLUX® Chemi Active GLP-1 (7-36) amide ELISA. The chemiluminescence ELISA features increased sensitivity to accurately quantify active GLP-1 (7-36) amide levels as low as 1.5 pg/mL with a 25 µL... - July 17, 2018 - ALPCO
ALPCO will promote its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at the American Diabetes Association’s 78th Scientific Sessions June 22-26, 2018 in Orlando, FL. - June 19, 2018 - ALPCO
CytoTest announces the continued expansion of its sales team with the addition of representatives in three major market territories. - January 30, 2018 - CytoTest Inc.
ALPCO announced it will feature a variety of products supported by its assay qualification program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo in San Diego August 1-3, 2017. Among these products is the Easy Stool Extraction Device and a Therapeutic Drug Monitoring ELISA portfolio. - July 25, 2017 - ALPCO
Coppe Laboratories conducted patient testing research in Wisconsin among 95 Lyme suspected patients. Within the 95 patient cohort, 41 were tested positive for Lyme disease. Of the 41 tested positive it was demonstrated in the research that approx. 17% of patients were also positive for Powassan Virus. - July 11, 2017 - Coppe Laboratories
The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader. - June 07, 2017 - ALPCO
ALPCO and InSphero will team up at the ADA’s 77th Scientific Sessions to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring glucagon secretion and glucose-regulated insulin assays. - June 06, 2017 - ALPCO
ALPCO will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this launch are two Zonulin ELISAs for the study of gut permeability and celiac disease, as well as therapeutic drug monitoring assays for IBD. - May 02, 2017 - ALPCO
New Research Identifies Patient-centric Strategies for Clinical Development with over 125 Global Research Opinion Leaders. - April 28, 2017 - Life Science Strategy Group, LLC
New Report Identifies Current and Future Wearable Technology Utilization and CRO Implications with 130 Clinical Outsourcing Decision Makers. - December 01, 2016 - Life Science Strategy Group, LLC
ALPCO is now offering a line of research assays for the investigation of common bacterial and parasitic gastrointestinal (GI) pathogens including Giardia lamblia, Cryptosporidium spp., Blastocystis hominis, Entamoeba histolytica/dispar, and Clostridium difficile. These assays can be used to research... - November 15, 2016 - ALPCO
ALPCO has released its new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA, the most sensitive active GLP-1 assay on the market. - November 09, 2016 - ALPCO
5-year Study Tracks Central Lab Performance and Identifies Opportunities for Pharma Sponsors to Improve Clinical Investigator Satisfaction. - October 24, 2016 - Life Science Strategy Group, LLC
ALPCO has launched its new STELLUX® Chemiluminescent Plate Reader, an economical and versatile system for any size lab. - September 20, 2016 - ALPCO
The new STELLUX® Chemi Active GLP-1 ELISA from ALPCO features superior sensitivity and requires only 10 µL of sample. - September 13, 2016 - ALPCO
ALPCO has released new and improved versions of their Total Adiponectin and HMW & Total Adiponectin ELISAs which allow researchers to confidently measure adiponectin for the study of high molecular weight (HMW) to total ratios. - August 17, 2016 - ALPCO
Pennsylvania Elected Officials to Participate in Ribbon-Cutting Ceremony and
Grand Opening Event; KinderPharm is pleased to announce that it will hold a Grand Opening event and Ribbon-Cutting ceremony for its new office at 100 Arrandale Blvd., Exton, Pennsylvania on Friday, August 26th from 1 p.m. to 3 p.m. The event will feature a ribbon-cutting ceremony at 1 p.m., food and refreshments, and industry networking. - August 16, 2016 - KinderPharm LLC
ALPCO now has a new broad range Periostin ELISA capable of measuring elevated levels of periostin consistent with current research. - June 07, 2016 - ALPCO
ALPCO recently announced the release of its Bioactive Leptin ELISA, offering diabetes and obesity researchers a new tool to differentiate between leptin resistance and non-functional leptin. The assay allows for the measurement of leptin in human serum through the process of binding leptin to leptin... - April 26, 2016 - ALPCO
ALPCO announced the launch of its new STELLUX® Chemi Human IL-6 ELISA - the first cytokine assay in the STELLUX® Chemiluminescence product line. - April 06, 2016 - ALPCO
ALPCO recently announced the release of its new NT-proBNP (1-76) ELISA, offering researchers investigating cardiovascular disease, kidney disease, and diabetes with a flexible, user friendly and cost effective tool. The assay is highly characterized to measure changes in levels of NT-proBNP, and can... - February 23, 2016 - ALPCO
ALPCO has released its new InhibiScreen Basophil Activation Test (BAT) which was developed and validated specifically for the evaluation of kinase inhibitors during early drug development. - February 16, 2016 - ALPCO
Italian research group uses Epitope Diagnostics' Chromogranin A ELISA kit in study to determine CgA as a potential prognostic marker in castration-resistant prostate cancer patients treated in abiraterone or enzalutamide. - February 11, 2016 - Epitope Diagnostics, Inc.
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step, allowing labs to improve sample processing time by up to 86%. - January 26, 2016 - ALPCO
The Global Health Investment Fund (GHIF) announced
today that it has provided a US$6 million [A$8.5 million] loan to Atomo Diagnostics (Atomo) to support scale-up of Atomo’s production operations and expansion of commercial activities related to the AtomoRapid™ rapid diagnostic test (RDT) platform. Funds will also be used to commercialise
a self-test solution for HIV and other infectious diseases. - January 16, 2016 - Atomo Diagnostics
Atomo Diagnostics awarded A$1.8 mil from the NSW Medical Device Fund
to develop innovative HIV self test in Australia. - November 28, 2015 - Atomo Diagnostics
VMRD is excited to announce release of version 2 (V2) of its bovine Anaplasma cELISA antibody test kit. This new version includes several long-requested customer improvements such as:
* Shorter run time: 30 minutes faster / 100 minutes total
* Easier to use: requires fewer steps and eliminates adsorption... - October 15, 2015 - VMRD
New Research Identifies Future Leadership and Benchmarks CRO Operational Performance with over 160 Clinical Outsourcing Decision Makers - October 07, 2015 - Life Science Strategy Group, LLC
Enzyme Linked Immunosorbent Assay (ELISA) is a widely used laboratory research assay designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones. ELISA is a very accurate, highly sensitive and specific immunoassay in comparison to other types of common protein... - October 03, 2015 - Altogen Labs
Ribonucleic Acid or RNA is a molecule critical to biology because it is behind the coding, regulation and expression of genes. With the RNA Interference or RNAi technology service offered by Altogen Labs it is possible to effectively regulate gene expression. Moreover, Altogen Labs has developed methods... - October 03, 2015 - Altogen Labs
Epitope Diagnostics introduces its novel fecal neutrophil gelatinase-associated lipocalin (NGAL) ELISA kit. This is the first commercial kit that is developed for measurement of NGAL levels in human stool sample. Fecal NGAL is potentially a better marker than those currently used in clinical practice. - September 01, 2015 - Epitope Diagnostics, Inc.
KinderPharm LLC., announced that it has acquired PKPD Bioscience, Inc., a clinical pharmacology and pharmacometric research and development company. The purchase will strengthen the capabilities of KinderPharm LLC to provide pediatric PK/PD modeling and simulation as well as Pop PK and sparse sampling. - September 01, 2015 - KinderPharm LLC
ALPCO has launched its new STELLUX® Chemiluminescent Total Adiponectin and HMW Adiponectin ELISAs. - August 25, 2015 - ALPCO
KinderPharm, a full-service contract research organization (CRO) dedicated exclusively to pediatric drug development, has raised $1 million from a Series A comprised of individuals, companies and angel investors. The $1 million investment will be used to further advance the clinical development of new medicines for children. - August 13, 2015 - KinderPharm LLC
ABR (now a VMRD division) announced today the availability of a new testing service that can detect the presence of bovine polyomavirus (BPyV) in animal origin products, master virus seeds, and other sample types. This infectivity assay, without using non-infectivity assays such as PCR, has the ability... - August 12, 2015 - VMRD
Starting on July 1, Cisbio US, Inc. will have exclusive access to ALPCO's colorimetric and STELLUX® Chemiluminescent Diabetes and Obesity products. - July 01, 2015 - ALPCO
ALPCO recently launched a brand new website. The site was designed and developed to offer their customers a new and improved experience when searching for and buying immunoassay products. The website’s key features allow for more intuitive browsing and navigation on any device.
ALPCO’s online... - June 16, 2015 - ALPCO
Epitope Diagnostics, Inc. has added a new ELISA kit to their product line to detect the total amount of 25-OH vitamin D2 and D3 in serum or plasma sample. This is a monoclonal antibody-based ELISA with a unique vitamin D releasing buffer for easy and reliable measurement of 25-OH vitamin D. - May 11, 2015 - Epitope Diagnostics, Inc.
Epitope Diagnostics, Inc. developed and produced a new ELISA Kit and rapid test with accessories for the detection of Clostridium difficile specific glutamate dehydrogenase (GDH). - May 10, 2015 - Epitope Diagnostics, Inc.
CytoTest Inc., the Uniformed Services University of the Health Sciences (USU), and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) announced today that they have signed a Cooperative Research and Development Agreement (CRADA).
Under the terms of the CRADA, CytoTest... - March 31, 2015 - CytoTest Inc.
Boston Healthcare today announced the appointment of Andreas Sander as Vice President and Managing Director for Boston Healthcare International GmbH, leading the European team and the firm’s activities in Germany and Europe out of Boston Healthcare’s Berlin office.
Mr. Sander brings over... - January 21, 2015 - Boston Healthcare
Boston Healthcare Associates, Inc. (BHA) and Cambridge Healthtech Institute (CHI) held an engaging, multi-stakeholder symposium surrounding the unique challenges and opportunities with the use of next-generation sequencing (NGS) in oncology care. Entitled, “Capturing the Value of Next-Generation... - December 12, 2014 - Boston Healthcare
ALPCO adds to their STELLUX® Chemiluminescent line of assays with the launch of the new Human C-peptide ELISA. - December 10, 2014 - ALPCO